RedHill’s COVID 19 Study Receives the FDA Go Ahead
RedHill Biopharma Ltd. (RDHL) announced that the FDA has approved its plan for starting a mid-stage study for testing out COVID 19 drug candidate. The company’s Investigational New Drug (IND) application for a Phase 2a clinical study deals with the evaluation of its investigational drug, opaganib in patients suffering from moderate-to-severe SARS-CoV-2 infection.
The company further reported that a total of 139 subjects have been given the drug candidate in ongoing and completed Phase 1 and 2 clinical studies in oncology indications.